Clinical trial
Randomized Trial of Loco-regional Radiotherapy Added to Pembrolizumab Alone or With Chemotherapy Versus Systemic Treatment Alone for Patients With Newly Diagnosed Head and Neck Squamous Cell Carcinoma With Synchronous Metastases
NCT04747054 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Randomized Trial of Loco-regional Radiotherapy Added to Pembrolizumab Alone or With Chemotherapy Versus Systemic Treatment Alone for Patients With Newly Diagnosed Head and Neck Squamous Cell Carcinoma With Synchronous Metastases
- Lead sponsor
- UNICANCER
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- December 1, 2021
- Completion date
- October 1, 2029
- Enrollment
- 102 (estimated)
- Sites
- 26
Conditions
As the registry lists them; a condition with its own page is linked.